Bispecifics in R/R MM: Key Data and Clinical Implications From ASH 2024 and Ongoing Trials

Opinion
Video

Panelists discuss how bispecific antibodies are reshaping the therapeutic approach in relapsed/refractory multiple myeloma (R/R MM), covering their mechanism of action, currently approved agents, and potential advantages. They explore how these therapies have transformed clinical decision-making, including optimal lines of therapy, patient selection, and best practices for integrating bispecifics into clinical practice.

Video content above is prompted by the following:

  • Let's now turn our attention to another class of therapies: bispecific antibodies. With several now approved by the FDA and combination trials underway, let's now discuss the landscape of bispecific antibodies—optimal lines of therapy, patient selection, and best practices for integrating these agents into clinical practice.
  • How are bispecific antibodies reshaping our therapeutic approach in relapsed/refractory multiple myeloma? Walk us through their mechanism of action, currently approved agents, potential advantages, and how these therapies have transformed your clinical decision-making.
Recent Videos
4 experts are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content